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Critical limb ischemia in diabetic patients is associated with high rates of morbidity and mortality. Subopti-
mal responses to the available medical and surgical treatments are common in these patients, who also
demonstrate limited vascular homeostasis. Neovasculogenesis induced by stem cell therapy could be a useful
approach for these patients. Neovasculogenesis and clinical improvement were compared at baseline and at
3 and 12 months after autologous bone marrow-derived mononuclear cell (BMMNC) transplantation in
diabetic patients with peripheral artery disease. We conducted a prospective study to evaluate the safety and
efficacy of intra-arterial administration of autologous BMMNCs (100–400 × 106 cells) in 20 diabetic patients
with severe below-the-knee arterial ischemia. Although the time course of clinical effects differed among
patients, after 12 months of follow-up all patients presented a notable improvement in the Rutherford-Becker
classification, the University of Texas diabetic wound scales, and the Ankle-Brachial Index in the target
limb. The clinical outcome was consistent with neovasculogenesis, which was assessed at 3 months by
digital subtraction angiography and quantified by MetaMorph software. Unfortunately, local cell therapy in
the target limb had no beneficial effect on the high mortality rate in these patients. In diabetic patients with
critical limb ischemia, intra-arterial perfusion of BMMNCs is a safe procedure that generates a significant
increase in the vascular network in ischemic areas and promotes remarkable clinical improvement.
Key words: Bone marrow-derived mononuclear cells (BMMNCs); Peripheral artery disease (PAD);
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INTRODUCTION of arteriolar enlargement and the formation of collateral
vessels that connect preocclusive arteries to the diseased
intraischemic arteries (29). Both mechanisms of com-Peripheral artery disease (PAD) is a common and se-
vere complication of diabetes mellitus and shows high pensatory neovasculogenesis are impaired in diabetic
patients due to endothelial progenitor cell dysfunction;rates of short-term morbidity and mortality. PAD in dia-
betic patients shows a distinctive pattern with occlusive this impairment explains the early extensive and acceler-
ated process of vascular complications in diabetes melli-arterial lesions that are typically located distally below
the knee (BTK); this limits the possibility of successful tus (12,20,31). The number of peripheral endothelial
progenitor cells in both type 1 and type 2 diabetic pa-mechanical revascularization by either surgical or endo-
vascular methods (6,7). Neovasculogenesis, which is the tients is decreased by more than 40% and is correlated
with an increase in glycosylated hemoglobin (HbA1c)development of a new vascular network, is a physiologi-
cal response to chronic ischemia and comprises two dif- (11,20). Subsequently, PAD is associated with a very
low number of endothelial progenitor cells in peripheralferent processes: angiogenesis and arteriogenesis. Angi-
ogenesis consists of the sprouting of capillaries and the blood (11).
Stem cell revascularization therapy for the treatmentformation of a capillary network that grows within an
ischemic area. In contrast, arteriogenesis is the process of diabetic nonrevascularizable PAD is a recent approach
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Table 1. Population Characteristics (Baseline Data)with encouraging preliminary results (13,15,30): clinical
improvement and the rescue of the Ankle-Brachial Index
Parameters Value(ABI) have been described in the majority of studies.
However, the optimum dose, source, and route of ad- Age (53–75 years old) 64.5 ± 5.8
ministration (intramuscular, intra-arterial, or combined) Male gender (%) 18 (90%)
are outstanding questions, which remain to be addressed Diabetes (years since diagnosed) 20.8 ± 5.8
Risk factors(24,28). In addition, most of the studies conducted to
Dislipidemia (%) 11 (55%)date are based on surrogate endpoints that reflect changes
Hypertension (%) 15 (75%)in limb perfusion and very few reports are available that
Smokers (%) 13 (65%)consist of angiographic demonstration of increased vas-
Coronary artery disease (%) 9 (55%)cularization after cell therapy. To address this, cell im-
HbA1c (%) 7.7 ± 1.0plantation would require ex vivo cell labeling (5,8,22),
Target limb findings
which is difficult to reconcile with good medical prac- Location: Right (%)/left 14 (70%)/6
tice principles (32). Furthermore, an increase in HbA1c Rutherford Becker
correlates with a decrease in endothelial progenitors Category 4 3 (15%)
(11,20), which means that diabetic patients with HbA1cs Category 5 11 (55%)
above 6.5% were excluded from previous studies. Category 6 6 (30%)
Failed revascularization interventionThe rationale of this study was that intra-arterial infu-
PTA/stent 10 (50%)sions of autologous bone marrow-derived mononuclear
Bypass 1 (5%)cells (BMMNCs), which contain endothelial progeni-
No run off 9 (45%)tors, that are perfused locally at severely diseased vascu-
Minor amputationslar beds in the lower limb could promote an early and
Transmetatarsal 5 (25%)
effective development of neovasculogenesis in diabetic Chopart’s 1 (5%)patients with critical limb ischemia (CLI). BTK occlusion
3 vessels 8 (40%)MATERIALS AND METHODS 2 vessels 11 (55%)
We conducted a prospective single-center study 1 vessel 1 (5%)
(ClinicalTrials.gov Identifier: NCT-00872326), phase I– tcpO2 (mmHg)* 39.74 ± 10.59
ABI 0.46 ± 0.19IIa, that aimed to assess the safety and efficacy of intra-
Ulcers (%) 8 (40%)arterial administration of BMMNCs in diabetic patients
with CLI. This clinical trial was promoted by Fundacio´n Values are shown as mean ± SD for 20 patients who fulfilled the fol-
Progreso y Salud under a noncommercial investigator- lowing inclusion criteria: age ≤75 years old, diabetes (type 1 or 2),
and severe ischemia (Rutherford-Becker categories 4/6) of at least onedriven grant and was approved by the local institutional
lower limb due to extensive below-the-knee arterial disease not suit-review boards, the regional Andalusian Ethics Commit-
able to revascularization. Revascularization interventions were per-
tee, and the Andalusian Initiative for Advanced Thera- formed 1–2 years before bone marrow-derived mononuclear cell
(BMMNC) transplantation. PTA, percutaneous transluminal angi-pies (9).
oplasty; BTK, below the knee; HbA1c, glycosylated hemoglobin;
tcpO2, transcutaneous partial oxygen pressure; ABI, Ankle-BrachialPatient Inclusion Index.
*Six patients with tcpO2 < 30 mmHg (22 ± 4 mmHg).Our population sample was composed of 20 patients
with severe limb ischemia, with no options of revascu-
larization, who were treated with autologous BMMNC
preparation. In the case of bilateral limb ischemia, the vascular work-up, which included measurement of sys-
tolic blood pressure at both the anterior and posteriortarget limb used in the study was the more severely af-
fected limb. All patients provided written informed con- tibial arteries, measurement of ABI, which is the quo-
tient of the highest ankle pressure and the highest bra-sent and fulfilled the inclusion criteria (Table 1). Of
these patients, 11 (55%) had undergone failed attempts chial systolic blood pressure and imaging studies that
consisted of conventional intra-arterial digital subtrac-of revascularization using PTA/stents or bypass in the
ischemic limb and 9 (45%) presented no run-off and tion angiography. Transcutaneous partial oxygen tissue
pressures (tcpO2) in the supine position were recordedwere not suitable for revascularization. CLI was diag-
nosed according to the recommendations of the current using an oxygen monitor (TCM400 Radiometer, Copen-
hagen, Denmark). To assess the severity of limb ische-TransAtlantic Inter-Society Consensus (TASC) (23).
Assessment of the peripheral circulation of patients mia, we followed the classification system proposed by
Rutherford et al. (26); wounds were graded and werewas performed at baseline and at 3 and 12 months, re-
spectively. This consisted of a complete noninvasive staged according to University of Texas Diabetic Wound
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Classification System (18). All patients were evaluated tion of ABI changes at the 3-month follow-up and the
changes in the Rutherford-Becker and University ofon a case-by-case basis by a dedicated multidisciplinary
vascular team that included interventional radiologists Texas classifications during the course of the study com-
pared to baseline values (obtained at the time of infu-and vascular surgeons.
sion).
Autologous BMMNC Preparation
Angiographic Quantification of NeovascularizationThe process of BMMNC preparation and administra-
tion was performed completely within the catheteriza- For each patient, a comparison of lower limb digital
subtraction angiography (DSA) images between baselinetion laboratory surgical room. After mild sedation and
local anesthesia, the iliac crest was punctured and aspi- and at the 3-month follow-up was performed. Both DSA
acquisitions were performed by a vascular fluoroscopicrated to obtain 60 ml of bone marrow preparation. This
sample was diluted in 40 ml of heparinized saline (20 UI imaging system (Infinix, Toshiba, Japan) and were fo-
cused on the BTK area; measurements were obtainednonfractionated heparin/ml). BMMNCs were separated
with a Ficoll density gradient (Amersham Pharmacia Bio- under the same acquisition and procedural parameters
(level of injection and contrast flow). DSA acquisitionstech, Uppsala, Sweden) and washed in PBS (Sigma, St.
Louis, MO, USA). Prior to the administration of the were sent to a core-lab (CABIMER, Seville Spain) for
quantitative analysis; a common area was selected forBMMNCs, the number of mononuclear cells and their
viability was determined and a sample of 0.5 ml was quantification (Fig. 1A). Quantitative analysis of the re-
sulting images was performed using MetaMorph v.6.3obtained for determination of the percentage of CD34+
cells by flow cytometry analysis (Citomics FC 500 using the Angiogenesis Tube Formation application
module. Minimum and maximum width vessels wereBeckman-Coulter). Finally, BMMNCs were filtered
through a cell strainer and diluted in 20 ml of saline to initially empirically chosen to fit angiographic value
ranges from 0.5 to 6 mm (thinnest to thickest tubule,fill a 50-ml syringe that was kept sealed until adminis-
tration. respectively). Analysis was performed using four inten-
sity values above the local background (400, 600, 800,
Intra-arterial Administration of BMMNCs and 1000 gray levels). As shown in Figure 1B, the final
process of quantification generated a segmented imageWhile the BMMNCs were being processed, target
limb arteries were selectively cannulated through a [16-bit autoscaled image where a value of 2 (white) rep-
resents the vessels and a value of 1 (green) representstransfemoral or transradial approach with an over-the-
wire catheter balloon that was advanced as distally as the nodes]. The numeric results are presented as mean ±
SEM of the intensity values above local background forpossible and positioned proximal to the occlusive vascu-
lar lesions, usually at the distal femoral or popliteal ar- each parameter. Statistical significance was assessed by
using a paired difference mean of each parameter paired-tery. At this point, the balloon was inflated to block
antegrade blood flow and the BMNMCs were slowly samples t-test (sig. two-tailed). The assessment of the
vascular network was focused on the measurement of itsinfused for 3 min. After infusion, the balloon was de-
flated and antegrade blood flow was restored. The num- extension and density: the extension of vascularity was
the sum of the arterial length (total tubule length) or theber of BMMNCs obtained ranged from 113.7 × 106 to
434.5 × 106 (mean 266.2 ± 81.89 × 106). The amount of arterial area (total tubule area); the vascular density,
which expressed the sprouting and vascular network for-CD34+ cells was 1.73 ± 0.43%, which resulted in a mean
infusion of 4.37 ± 1.54 × 106 CD34+ cells (ranging from mation, was measured by counting the number of seg-
ments (total number of vessel segments connecting2.14 × 106 to 7.81 × 106 cells). The site of BMMNC in-
fusion was distal femoral artery in 1 patient, popliteal branch points and/or ends) and the number of branch
points (total number of junctions connecting segments).artery in 13 patients, and BTK in 6 patients. In 6 pa-
tients, the procedure was performed using a transradial The schematic illustration of those parameters is indi-
cated in Figure 1C. Neovascularization was character-approach that required extra-large over-the-wire bal-
loons of 200-cm length. ized as a significant increment of extension and/or den-
sity of the vascular network at the 3-month follow-up
Evaluation of BMMNC Transplantation Efficacy compared to baseline.
The efficacy of BMMNC transplantation was as-
Safety Assessmentsessed by the development of neovascularization down-
stream of the site of cell infusion. The primary endpoint The safety assessment checked for possible adverse
events related to the intra-arterial infusion of BMMNCs,was the angiographic evaluation of neovascularization,
with quantification of vascular network growth at the 3- which was initially performed 24 h after the procedure,
focused on the risk of thrombogenic events. These as-month follow-up. Secondary endpoints were the evalua-
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Figure 1. Angiographic quantification steps to assess neovascularization. (A) Baseline (Pre) and 3 month follow-up (Post) identical
images from a selected common same area to be quantified. (B) Segmented image generated by MetaMorph v.6.3 to evaluate the
degree of vascularization [tubes are displayed in white and the nodes in green; segments (blue) and the branch points (orange) are
not visible]. (C) Schematic illustration of the four parameters selected for the quantification.
sessments were then followed up with planned clinical rovascular disease; 7 patients were referred with symp-
tomatic vascular disease other than PAD (coronary andvisits at 1, 3, and 12 months after the procedure; severe
adverse events were reported to the promoter of the cerebrovascular) and all the patients presented with bi-
lateral limb symptoms at baseline. The mean ABI re-study.
sults, as an expression of limb perfusion, reflected the
RESULTS severity of the clinical manifestations for both limbs:
0.49 ± 0.23 for the right limb and 0.56 ± 0.17 for the leftBaseline Clinical Characteristics
one. Selected target lower limbs (14 right and 6 leftTwenty patients (Table 1) average age of 64 ± 6
lower limbs) were severely symptomatic (100% of pa-years old (51–75 years old), who consisted of 18 males
tients had Rutherford-Becker category of 4/6), with aand 2 females, were included. All but one patient (P13)
mean ABI value of 0.46 ± 0.19. In most patients, thehad type 2 diabetes. Diabetes treatment consisted of in-
contralateral extremities were also affected, althoughsulin in 13 patients (in 2 patients, this was administered
they were less symptomatic. The University of Texasin combination with oral antidiabetic agents) and antidi-
diabetic wound classification showed unhealed ulcersabetic oral agents alone for the remaining 7 patients. The
for 11 patients (7 grade C3, 3 grade C2, and 1 grademean glycosylated hemoglobin was 7.7 ± 1.0% (ranging
A2). The remaining 9 patients displayed healed trophicfrom 5.7 to 9.7%), which is a value similar to that re-
lesions at the start of the trial and target limbs were clas-ported to induce impaired proliferation, adhesion, and
sified as C1, C0, and A0, with 3 patients for each cate-incorporation of endothelial progenitor cells into vascu-
gory.lar structures (31). The majority of our patients suffered
severe microvascular complications: diabetic neuropathy Quantitative Assessment of Neovascularization(25) in 17 patients, retinopathy in 12, and diabetic ne-
phropathy in 4 patients (no patient was undergoing Systematic angiographic review to evaluate BTK
neovascularization was performed before and 3 monthshemodialysis). There was also extensive spread of mac-
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after the infusion of BMMNCs for all patients, except routine quantitative analysis was performed to assess
neovascularization. MetaMorph software was used tofor one, who died before angiographic follow-up. Com-
parison of angiographic images showed a widespread evaluate the development of a vascular tree downstream
of the site of cell infusion to provide information aboutimprovement in BTK vascularization (Fig. 2A) down-
stream of the site of cell administration (Fig. 2B). Vas- the extension of vascularity and the density of the vascu-
lar network. Neovascularization was considered as thecular improvement presented two patterns, which were
usually combined. One pattern was the development of net improvement in vascular extension and/or the den-
sity at the 3-month follow-up compared to baseline.a vascular network, which expanded from the main ves-
sels (tibial anterior, tibial posterior, or peroneal arteries) Quantification showed that substantial neovasculariza-
tion was achieved by the majority of patients: 13 pa-to the periphery of the calf that was comprised of ta-
pered and highly branched vessels that reached the sub- tients (68%) at the 3-month follow-up showed an im-
provement in vascularity with an increase in vascularcutaneous tissue; the other consisted of an increase in
the diameter of collateral preexisting vessels. Another extension and/or vascular density variables. Regarding
variables that measured vascular extension, at the 3-angiographic finding, which was detected in 3 patients
(P4, P9, and P13), was the development of a rapid (fistu- month follow-up, there was a significant increase in the
overall length of the vessels in 11 patients (58%),lous) arteriovenous transition, with simultaneous filling
of downstream arteries and upstream venous drainage; whereas 10 patients (53%) presented with significant in-
creases in total vessel area. Regarding the density of thethis unexpected finding was particularly remarkable in
one patient (P9), which showed the presence of multiple sprouting network vascularity, at the 3-month follow-up
11 patients (58%) presented with significant increases instructures with the appearance of angioma-like structures
(defined as a rapid arteriovenous transition during the the total number of vessel segments connecting branch
points and/or ends; 10 patients (53%) presented withearly phase of arteriography that showed unique or mul-
tiple focal contrast-enhanced formations, as assessed by significantly increased branch point variables (the total
number of junctions connecting segments). Thus, theangiographic analysis) (Figure 3A). These patients did
not present with any clinical complications at follow-up. overall quantification of our population showed a statis-
tically significant increase in vascular extension [totalBesides this visual assessment of vascularization, a
Figure 2. Angiographic evaluation at 3 months follow-up after autologous bone marrow-derived mononuclear cell (BMMNC)
administration. (A) Patient with baseline patency of only peroneal artery presented at 3 month follow-up an outstanding vascular
network growth, with collateral arteries enlargement and denser network due to proliferation of new branches. (B) Angiographic
image at baseline (left) showing the site of autologous BMMNC administration (black arrows) and at 3 months after (right) where
new collateralization of capillary vessels was appreciated.
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Figure 3. Angiographic evaluation and quantification of neovascularization. (A) Patient with base-
line single vessel patency of peroneal artery presented an unexpected finding of fistulous arterio-
venous paths (angioma-like structures). (B) Angiographic data of vascular extension (total tube
area and length) and vascular density (junction or branch points and vascular segments) at below-
the-knee vascular region were quantified and compared between baseline (black) and 3 months
follow-up (gray). There was significant increase of each variable, which expresses the appearance
of neovascularization induced by intra-arterial administration of autologous BMMNCs. Statistical
significance was assessed by using a paired samples t-test (sig. two-tailed).
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tubules length and total tubules area with a paired differ- superficial ulcer (A1) located on the first toe. Referring
physicians reported that the infusion of BMMNCs in-ence mean of 196.33 mm, sig. 0.00022 (two-tailed), and
444.57 mm2, sig. 0.002 (two-tailed), respectively] and duced an unexpected benefit of an improvement in the
healing process, not only for ulcers (Fig. 4B), but evensprouting network [segments and branch point with a
paired difference mean of 28.89, sig. 0.00017 (two-tailed) for minor amputations. Furthermore, early clinical bene-
fits of cell infusion consisted of patients having a wide-and 11.53, sig. 0.00015 (two-tailed), respectively] (Fig. 3B).
spread perception of less limb pain, an increase in pain-
Clinical Changes Induced by BMMNCs free walking, and warmness in the target limb. At the 3-
month follow-up, patients (one deceased, P16) mani-One year after BMMNCs infusion, there was a re-
markable improvement in clinical status in most of the fested clear clinical benefit, with the exception of two
patients (P5 and P11) who also showed no angiographictarget limbs. All 16 patients who were alive after the
first year of follow-up presented with a notable improve- improvement. In addition to the clinical improvement
for the majority of the sample population, there was ament in both Rutherford-Becker and University of Texas
classification (Table 2). The University of Texas dia- significant increase in ABI (from 0.46 ± 0.19 to 0.70 ±
0.23, sig. 0.019) in the target limb at the 3-month fol-betic wound classification reflected complete healing of
trophic lesions without signs of ischemia or infection in low-up (Fig. 4C) and even more at 12-month follow-up
(from 0.46 ± 0.19 to 0.81 ± 0.19, sig. 0.000). The tcpO2every patient, except for one (P9), who presented with a
increased in most patients and also for those with tcpO2 <
30 mmHg (22 ± 4 mmHg at baseline vs. 40.6 ± 18.3 at
Table 2. Improvement of Clinical Outcomes After Implant 3-month follow-up).
of BMMNCs: Evolution of Rutherford-Becker and University During the 1-year follow-up period, there were no
of Texas Classification Before (Baseline) and 3 and 12
major amputations in any patient, even for the nontargetMonths After
limb. However, 7 patients did undergo minor toe ampu-
tations, all of which had Rutherford-Becker categoriesBaseline 3 Months 12 Months
Cases (%) Cases (%) Cases (%) (5/6) at baseline: 5 patients underwent amputations in
the target limb (P2, P7, P8, P19: transmetatarsal and P16
Rutherford-Becker chopart’s), one underwent an amputation in the nontar-
categories get limb (P1) and the other patient (P5) underwent minorCat. 0 0 4 (25%) bilateral transmetatarsal amputations. All toe amputa-Cat. 1 5 (26.4%) 9 (56.25%)
tions, except in one patient (P9, due to shoe trauma thatCat. 2 12 (63.1%) 3 (18.75%)
provoked osteomyelitis of the first toe), were scheduledCat. 3
prior to the BMMNC infusion (wet necrosis leading toCat. 4 3 (15%)
dry necrosis) and were performed during the first 3Cat. 5 11 (55%) 2 (10.5%)
Cat. 6 6 (30%) months.
University of Texas Four patients (P2, P7, P12 and P16) died due to is-
Stage A chemic cardiac disease complications that were unre-
No Ulcer 1 (5%) lated to the cell therapy. The mortality rate in our popu-
A0 3 (15%) 15 (79%) 14 (87.5%) lation (20%) was similar to that in other studies (2) and
A1 2 (10.5%) 1 (6.25%)
was highly dependent on cardiac or cerebrovascularA2 1 (5%) 1 (5.3%)
complications (14).A3
Local neovascularization and clinical improvement inStage C
these patients prior to death was similar to the rest ofC0 3 (15%)
the sample group. No additional deaths were observedC1 3 (15%)
after 12 months. Taken together, these results suggestC2 3 (15%)
C3 6 (30%) clear clinical and angiographic improvements that result
from autologous BMMNC implantation. In 12 patients,
One patient (5%) died in the first 3 months and another three (15%)
we observed that the clinical follow-up benefit matchedin the first 12 months. No more deaths in the population analyzed (16
patients > 24 months). Rutherford-Becker categories: Cat 0, asymp- the angiogenic data at 3 months, whereas in the other
tomatic; Cat 1, mild claudication; Cat 2, moderate claudication; Cat 3, patients, the clinical recovery was slower and 3 patients
severe claudication; Cat 4, rest pain; Cat 5, minor tissue loss; Cat 6, (18.75%) showed neither angiographic nor clinical im-ulceration or gangrene. The University of Texas uses a system of
wound grade and stage to categorize wounds by severity. Wounds are provement and/or the persistence of trophic lesions.
graded by depth (grades 0, 1, 2, and 3). Within each wound grade, Overall agreement between angiography and clinical
there are four stages: clean wounds (A), nonischemic infected wounds
status at 3 months was observed in approximately 80%(B), ischemic wounds (C), and infected ischemic wounds (D). Values
in bold indicate a clear improvement rate in high % of the population. of patients.
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Figure 4. Neovascularisation and clinical correlation. (A) The 3-month angiography showed increased vascular network perfusing
(inner circle) the area of trophic lesion, favoring ulcer healing. (B) Baseline unhealed ulcer at inner malleolus improved after
autologous BMMNC administration. (C) Average of ankle-brachial index (ABI) showing an increase from 0.46 ± 0.19 to 0.70 ±
0.23 of target limb at 3 months. Values are shown as mean ± SD and statistical significance was performed using paired t-test.
Safety Assessment In this scenario, the clinical benefits of stem cell ther-
apy have been reported in several studies. The Thera-No procedural complications during the cell adminis-
peutic Angiogenesis by Cell Transplantation trialtration were reported: even in low-perfusion areas, the
(TACT) was the first study that demonstrated an effec-infusion of BMMNCs did not cause any embolic events.
tive role of the intramuscular administration of BMMNCsDuring the first year, there were no adverse events di-
for CLI, with a transient (1 month and 6 months) im-rectly related to BMMNCs transplantation.
provement in the severity of rest pain (21,30). Moreover,
Amann et al. showed that bone marrow cell transplanta-
DISCUSSION tion improved leg perfusion and promoted leg salvage in
patients with end-stage CLI caused by peripheral arteryThe results of our study strongly suggest that intra-arte-
rial implantation of low doses of autologous BMMNCs disease (1). Based on preclinical studies (19), several
unresolved issues still remain; these include the idealinto ischemic limbs of diabetic patients induces the de-
velopment of significant and functional neovasculariza- type of cells (BMMNCs, CD34+ cells, mesenchymal
stem cells, combinations) that should be used, the dosetion. To our knowledge, this is the first study in which
the vascular area and vascular density in the ischemic and route of administration, and the profile of patients
who may receive the greatest benefit.region has been quantified using MetaMorph software.
Furthermore, the angiographic improvement observed The main strengths of this study include the follow-
ing: i) the target population was focused on diabetic pa-correlated well with the clinical benefit during the first
year of follow-up. Interestingly, 5 patients continued to tients, whereas other studies recruited patients from dif-
ferent pathologies (Buerger, tromboangeitis obliterans,make notable clinical improvements after 2 years of fol-
low-up. diabetes mellitus, etc.); ii) intra-arterial administration of
BMMNCs that was as distal as possible and was down-CLI represents a major concern due to its prevalence
among diabetic patients, its poor prognosis, and its lim- stream of the diseased arterial bed; iii) the primary end-
point was the angiographic confirmation of neovasculari-ited treatment options (6,7). Surgical or endovascular re-
vascularization options are limited due to the poor arte- zation in ischemic limb areas at the 3-month follow-up,
which was quantified by MetaMorph software; and iv)rial outflow in diabetics (14).
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the dose used was 10 times smaller (2.66 ± 0.8 × 108 and 4 MethaMorph parameters improved) while patients
with higher HbA1c showed a significant improvementcells) than the dose (1–5 × 109 cells) used in previous
studies (1,30). Recent studies have proved the feasibility (ABI from 0.35 to 0.72; Rutherford-Becker categories
5/6 to 1/0; Texas from C2-A2-A0 to A1-A0; and 2–3and the safety of intra-arterial administration of BMMNCs,
single or combined with intramuscular infusion (3,13, MethaMorph parameters improved). These results sug-
gest that functional endothelial progenitors from the33). A recent clinical trial (13) that compared intra-
arterial BMMNC administration with intramuscular bone marrow (presumably devoid of the glycosylation
damage) are fully operative in terms of neovasculariza-BMMNC administration showed no significant benefit
of one of the other; however, there is a trend that favors tion. Besides this improvement in the majority of pa-
tients, the assessment of ABI also showed a significantthe intra-arterial route in terms of pain relief and limb
salvage. In our study, BMMNCs were infused down- increase at the 3-month follow-up compared to baseline.
The appearance of angiomatous structures down-stream into lower limb arteries and, for all but one pa-
tient, cells were distally infused at the popliteal artery or stream of the BMMNC perfusion point could be a matter
of concern. Vascular endothelial growth factor (VEGF)below while discontinuing antegrade blood flow for 3
min, which guaranteed homing of a greater number of gene therapy for CLI has been associated with the occur-
rence of angioma (16). Administration of BMMNCs intoBMMNCs to the ischemic target area.
To date, the assessment of the efficacy of cell therapy severe ischemic tissues with upregulated endothelial re-
ceptors to angiogenic cytokines could trigger a hyperac-in severe PAD was based on surrogate endpoints (relief
of pain and decrease of amputation rate) or functional tive response in creating new vessels. Three patients pre-
sented with angioma-like structures, with high contrasttests (ABI and tcpO2), which reflect the perfusion of the
ischemic limb (1,27). None of the previous studies dem- intensity and rapid transition to venous circulation repre-
senting increased angiogenesis with low-resistance flowonstrated neovascularization in diabetic patients with
CLI using a quantitative method. Neovascularization to adjacent venules; luckily these patients experienced
no complications. As previously reported, 1-year mortal-may be demonstrated either directly or by angiographic
follow-up or through the pathological examination of ity for patients with severe PAD is approximately 20%
and is mostly dependent on cardiovascular complica-amputated limb samples (32) that are not obtained from
the injection sites. In our study, MetaMorph software tions (1,2,14). In our study, 4 deaths were registered dur-
ing the first year. Exitus were due to cardiovascularenabled the quantification of the vascular tree (4,10,17).
The majority of patients presented with a significant in- deaths that occurred at least 3 months after the proce-
dure and were unrelated to BMMNCs therapy. However,crease in vascularity in the ischemic BTK areas after
cell infusion; this increase in neovascularization was there was a significant increase in local neovasculogen-
esis for the majority of the patient population and thecorrelated with the clinical status, with notable symp-
tomatic improvement in the target limb for all at the 1- subsequent decrease in the number of amputations (1)
and overall mortality was similar to that reported inyear follow-up. A widespread improvement in Ruther-
ford-Becker grade, ABI, and an almost complete healing PAD (2,14).
of previous diabetic trophic lesions in the lower extremi-
CONCLUSIONSties were observed 3 months and 1 year posttransplanta-
tion. The following conclusions were drawn: 1) intra-arte-
In contrast with other studies in which patients with rial transplantation of BMMNCs in diabetic patients
HbA1cs above 6.5% were excluded (13,15,21,30), our with severe PAD is an effective approach that is associ-
patients displayed a broad range of HbA1c values (from ated with short-term induction of neovascularization; 2)
5.7% to 9.7%), which were quite similar to those in- our population manifested clinical improvement in the
cluded in the Amann et al. study (1). This allowed us to lower limb, which included better ulcer healing, in-
test whether the baseline and follow-up value of HbA1c creased ABI values, increased leg temperature, and other
determines the clinical outcome. A direct comparison local signs that are indirect indicators of collateral vessel
between the patients with an HbA1c below 6.5% (P14, formation; 3) the dose used is 10 times smaller than that
P17, and P19) and those with higher HbA1cs (P3, P9, used in previously published studies; 4) intra-arterial
and P13) demonstrates that this is not the case. In both BMMNC transplantation is a safe procedure, with no
groups, the HbA1c remained at the baseline values. We adverse events resulting from stem cell therapy; and 5)
observed similar benefits in patients with all levels of diabetic patients with HbA1cs above 6.5% should not be
HbA1c. However, in those patients with lower HbA1c excluded from these studies or from potential treatment.
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